ANDA 76252, held by Teva. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 76252 (Ondansetron Hydrochloride), held by Teva, was first approved by FDA on Jun 25, 2007, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2007 | Original application | Approved | None posted |
| Ondansetron HydrochlorideEQ 4MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| Ondansetron HydrochlorideEQ 8MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| Ondansetron HydrochlorideEQ 24MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| May 14, 2018 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 19, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 19, 2014 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 13, 2012 | Supplement 6Labeling | Approved | None posted |
| Nov 30, 2010 | Supplement 5Labeling | Approved | None posted |
| Oct 31, 2007 | Supplement 2Labeling | Approved | None posted |
| Jun 25, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters